2013
DOI: 10.38109/2225-1685-2013-2-15-26
|View full text |Cite
|
Sign up to set email alerts
|

Macitentan: The Evolution of the Class Endothelin Receptor Antagonists to Improve Efficacy and Safety of Pah Treatment

Abstract: Pulmonary arterial hypertension (PAH) is a severe progressive disease, characterized by advanced remodeling of small pulmonary arteries and arterioles, which ultimately leads to right heart failure and death. Due to discovery of PAH pathophysiological targets, new medications have been developed and implemented into clinical practice. These medications compensate the deficiencies of endogenous prostacyclin and nitric oxide and also block the effects of endothelin-1 (ET-1). The role of the latter in PAH pathoph… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
references
References 15 publications
0
0
0
Order By: Relevance